Alzheimer’s drug Leqem­bi gets full OK; Biotech’s H1 by the num­bers; Bring­ing Leerink back; Against AI over­hype; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Long­time read­ers would be fa­mil­iar with our an­nu­al spe­cial re­port hon­or­ing women in bio­phar­ma R&D. This year we’ve moved the pub­li­ca­tion of the pro­files and the ac­com­pa­ny­ing event to Ju­ly. We would love to see you there — you can find more de­tails here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER